Pure Global

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation - Trial NCT06212102

Access comprehensive clinical trial information for NCT06212102 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bedaya Hospital and is currently Not yet recruiting. The study focuses on Infertility. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06212102
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06212102
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial

Study Focus

Infertility

Progestin primed ovarian stimulation

Interventional

drug

Sponsor & Location

Bedaya Hospital

Giza, Egypt

Timeline & Enrollment

Phase 2

Feb 01, 2024

Dec 01, 2026

120 participants

Primary Outcome

Medications costs per retrieved oocyte

Summary

The aim of this randomized controlled trial was to compare the efficacy and
 cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in
 poor responders undergoing double stimulation protocol.

ICD-10 Classifications

Female infertility
Male infertility
Female infertility, unspecified
Female infertility of other origin
Female infertility of uterine origin

Data Source

ClinicalTrials.gov

NCT06212102

Non-Device Trial